ResMed (RMD) slides as shares hit a 52-week low amid renewed post-earnings scrutiny

ResMed Inc. (RMD) is down 6.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The drop appears tied to a renewed wave of selling after its late-April quarterly update, as investors focused on a slight revenue shortfall versus expectations and digested several near-term “headline” items (leadership transition and M&A), which can amplify downside when sentiment is already fragile. The move also lines up with the stock testing fresh 52-week lows, which can trigger additional technical and risk-management selling.

Details:

Shares traded to a new 52-week low around $198.60 during Friday’s session, extending a difficult 12-month stretch for the stock.

In its fiscal Q3 2026 results (reported April 30, 2026), ResMed posted non-GAAP EPS of $2.86 and revenue of about $1.43 billion, with management highlighting margin expansion and continued demand strength.

ResMed also announced a CFO transition effective in early May 2026, with the long-tenured finance chief retiring and a new CFO stepping in.

The company disclosed an agreement to acquire Noctrix Health for $340 million, with an expected close on or around June 1, 2026, adding another near-term variable for investors to handicap.

Sources:

ResMed Investor Relations / SEC filings, Investing.com, MassDevice, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$RMD Insider Trading Activity

$RMD insiders have traded $RMD stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.

Here’s a breakdown of recent trading of $RMD stock by insiders over the last 6 months:

MICHAEL J. FARRELL (Chairman and CEO) has made 0 purchases and 5 sales selling 24,955 shares for an estimated $6,239,685.
PETER C FARRELL has made 0 purchases and 5 sales selling 10,000 shares for an estimated $2,473,660.
BRETT SANDERCOCK (Chief Financial Officer) has made 0 purchases and 4 sales selling 4,000 shares for an estimated $967,250.
MICHAEL J RIDER (Global General Counsel) has made 0 purchases and 3 sales selling 150 shares for an estimated $37,295.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive RMD Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$RMD Hedge Fund Activity

We have seen 449 institutional investors add shares of $RMD stock to their portfolio, and 493 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

AMUNDI added 587,872 shares (+123.9%) to their portfolio in Q1 2026, for an estimated $131,965,506
DIAMANT ASSET MANAGEMENT, INC. added 402,164 shares (+21166.5%) to their portfolio in Q1 2026, for an estimated $90,277,774
MARSHALL WACE, LLP added 381,296 shares (+inf%) to their portfolio in Q1 2026, for an estimated $85,593,326
TWO SIGMA INVESTMENTS, LP added 312,468 shares (+inf%) to their portfolio in Q1 2026, for an estimated $70,142,816
VOLORIDGE INVESTMENT MANAGEMENT, LLC added 309,614 shares (+244.4%) to their portfolio in Q1 2026, for an estimated $69,502,150
RENAISSANCE TECHNOLOGIES LLC removed 304,480 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $68,349,670
PRICE T ROWE ASSOCIATES INC /MD/ removed 297,795 shares (-38.7%) from their portfolio in Q1 2026, for an estimated $66,849,021

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$RMD Analyst Ratings

Wall Street analysts have issued reports on $RMD in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

JP Morgan issued a "Overweight" rating on 04/15/2026

To track analyst ratings and price targets for $RMD, check out Quiver Quantitative's $RMD forecast page.

$RMD Price Targets

Multiple analysts have issued price targets for $RMD recently. We have seen 7 analysts offer price targets for $RMD in the last 6 months, with a median target of $275.0.

Here are some recent targets:

Nathan Treybeck from Wells Fargo set a target price of $227.0 on 05/01/2026
Craig Wong-Pan from RBC Capital set a target price of $321.0 on 05/01/2026
Brett Fishbin from Keybanc set a target price of $290.0 on 04/27/2026
Laura Sutcliffe from Citigroup set a target price of $340.0 on 04/09/2026
Adam Maeder from Piper Sandler set a target price of $275.0 on 01/30/2026
Jonathan Block from Stifel set a target price of $265.0 on 01/30/2026
Joe Vruwink from Baird set a target price of $275.0 on 12/16/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.